Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for IMPAX Laboratories, Inc.�
-1.02 (-2.71%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.25 - 37.38
52 week 21.34 - 39.49
Open 37.35
Vol / Avg. 798,705.00/750,106.00
Mkt cap 2.61B
P/E 54.70
Div/yield     -
EPS 0.67
Shares 71.25M
Beta 1.10
Inst. own 86%
Feb 24, 2015
Q4 2014 Impax Laboratories Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 24, 2015
Q4 2014 Impax Laboratories Inc Earnings Call - 8:30AM EST - Add to calendar
Jan 13, 2015
Impax Laboratories Inc at JPMorgan Healthcare Conference
Nov 11, 2014
Impax Laboratories Inc at Credit Suisse Healthcare Conference
Nov 4, 2014
Q3 2014 Impax Laboratories Inc Earnings Release
Nov 4, 2014
Q3 2014 Impax Laboratories Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 9.96% 19.80%
Operating margin 16.14% 28.08%
EBITD margin - 14.32%
Return on average assets 5.87% 10.88%
Return on average equity 7.18% 13.49%
Employees 973 -
CDP Score - -


30831 Huntwood Avenue
United States - Map
+1-510-2406000 (Phone)
+1-510-4713200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established drug names. The Impax Division is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Division is also engaged in the sale and distribution of Zomig (zolmitriptan) products.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
G. Frederick Wilkinson President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 46
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Pharmaceutical Division
Age: 55
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq Senior Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Larry Hsu Ph.D. Director
Age: 65
Bio & Compensation  - Reuters
Mary K. Pendergast J.D. Director
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Allen Chao Ph.D Independent Director
Age: 68
Bio & Compensation  - Reuters
Nigel Ten Fleming Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters